Zacks Research Brokers Increase Earnings Estimates for HALO
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report issued on Friday, December 26th. Zacks Research analyst Team now forecasts that the biopharmaceutical com
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report issued on Friday, December 26th. Zacks Research analyst Team now forecasts that the biopharmaceutical com
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
